Acesion Pharma Strengthens Clinical Team with Key Appointments

Acesion Pharma, a Danish pharmaceutical company developing novel treatments for atrial fibrillation (AF), the most common cardiac arrhythmia, today announced that it has recruited Anders Gaarsdal Holst as its Chief Medical Officer (CMO) to succeed Nils Edvardsson, who will continue to support the company as Medical Adviser. In addition, Acesion Pharma has further strengthened the clinical team by recruiting Birgitte Vestbjerg as Director Clinical Operations.

Read more

By Optimum

For more information about Optimum Strategic Communications, please get in touch

We'd love to hear from you...